Up Next
0
Faber Report: Biogen Idec Buying Stake in MS Drug
CNBC's David Faber reports Biogen Idec is buying Elan's stake in MS drug Tysabri for $3.25 billion plus royalties.
Share
Faber Report: Biogen Idec Buying Stake in MS Drug
CNBC's David Faber reports Biogen Idec is buying Elan's stake in MS drug Tysabri for $3.25 billion plus royalties.
Date: 2/6/13
Views: 62
Video by:  CNBC
 
Follow us:
Loading... 1 of 167
Today's Most Watched Videos
Related Videos
Loading... 1 of 56